メトロノーム療法による術後補助的化学療法を行った犬の悪性腫瘍28例
28頭の犬の悪性腫瘍症例に術後補助的化学療法として、CPMを10～35 mg/m2およびピロキシカム0.3 mg/㎏をそれぞれ一日おきに投与する低用量メトロノーム療法を行い、腫瘍抑制効果ならびに出血性膀胱炎（SHC）の症状である血尿および膀胱炎症状の発現について評価した。その結果、脾臓血管肉腫、膀胱移行上皮癌では従来と同等の効果が得られたが、低用量メトロノーム療法の効果はみられなかった。また、外科切除の成否が予後を左右する重要な因子であることが再確認された。SHCに関しては、膀胱移行上皮癌2頭を除く26頭中3頭（11.5％）で血尿および膀胱炎症状が認められたが、CPMの投与量、投与期間と血尿の...
Saved in:
| Published in | 日本獣医麻酔外科学雑誌 Vol. 51; no. 2; pp. 16 - 22 |
|---|---|
| Main Authors | , , , , , , , |
| Format | Journal Article |
| Language | Japanese |
| Published |
一般社団法人 日本獣医麻酔外科学会
2020
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 2189-6623 2189-6631 |
| DOI | 10.2327/jjvas.51.16 |
Cover
| Abstract | 28頭の犬の悪性腫瘍症例に術後補助的化学療法として、CPMを10～35 mg/m2およびピロキシカム0.3 mg/㎏をそれぞれ一日おきに投与する低用量メトロノーム療法を行い、腫瘍抑制効果ならびに出血性膀胱炎（SHC）の症状である血尿および膀胱炎症状の発現について評価した。その結果、脾臓血管肉腫、膀胱移行上皮癌では従来と同等の効果が得られたが、低用量メトロノーム療法の効果はみられなかった。また、外科切除の成否が予後を左右する重要な因子であることが再確認された。SHCに関しては、膀胱移行上皮癌2頭を除く26頭中3頭（11.5％）で血尿および膀胱炎症状が認められたが、CPMの投与量、投与期間と血尿の発現には明らかな関連性はみられなかった。しかしながら、投与量が最も多かった1例が重度なSHCを発症していることから、投与量は重要な発生因子になると思われた。 |
|---|---|
| AbstractList | 28頭の犬の悪性腫瘍症例に術後補助的化学療法として、CPMを10～35 mg/m2およびピロキシカム0.3 mg/㎏をそれぞれ一日おきに投与する低用量メトロノーム療法を行い、腫瘍抑制効果ならびに出血性膀胱炎（SHC）の症状である血尿および膀胱炎症状の発現について評価した。その結果、脾臓血管肉腫、膀胱移行上皮癌では従来と同等の効果が得られたが、低用量メトロノーム療法の効果はみられなかった。また、外科切除の成否が予後を左右する重要な因子であることが再確認された。SHCに関しては、膀胱移行上皮癌2頭を除く26頭中3頭（11.5％）で血尿および膀胱炎症状が認められたが、CPMの投与量、投与期間と血尿の発現には明らかな関連性はみられなかった。しかしながら、投与量が最も多かった1例が重度なSHCを発症していることから、投与量は重要な発生因子になると思われた。 |
| Author | 及川, 嗣章 飯塚, 邦洋 高澤, 和子 阿部, 泰朗 畠山, 洋之 木内, 充 太田, 宣浩 佐藤, 敏彦 |
| Author_xml | – sequence: 1 fullname: 及川, 嗣章 organization: 及川動物病院 – sequence: 1 fullname: 木内, 充 organization: エルどうぶつクリニック – sequence: 1 fullname: 飯塚, 邦洋 organization: ヒロアニマルクリニック – sequence: 1 fullname: 畠山, 洋之 organization: ひいらぎ動物病院 – sequence: 1 fullname: 佐藤, 敏彦 organization: さとう動物病院 – sequence: 1 fullname: 太田, 宣浩 organization: アルフ動物病院 – sequence: 1 fullname: 高澤, 和子 organization: タカサワ動物病院 – sequence: 1 fullname: 阿部, 泰朗 organization: 岩手どうぶつ医療センター |
| BookMark | eNo9UMtKw0AAXKSCtfbkd6Rmd7Ob9CJI8VEoeNHzstlutKFWSYrgzSQKpa0eFEVF0FJQtNaLV-nPrGnyGVItvcwMzDAMswgyjcOGBGAZ6gWEkbniusfcLxBYgHQOZBG0ihqlGGZmGuEFkPf9mq1jaBq6hfUsYCrqqailoqGKLlX0raLn5D4cf92oYKDClgo7ae86HnXT_mPcfksezuLubTx8mWbCq7TXVUFfBU9J-0MFn-PwfXz6mp4PkrsLZP2MOktg3uF1X-annAO7G-s7pS2tsr1ZLq1VNBcZVNcQFSbhqAjlZJhNqE1tk1jYsCh2HFEU1ECi6mApLaRjbOqU8KopEEWEGA4SOAdW_3tdv8n3JDvyagfcO2Hca9ZEXbK_cxiBDE0A0pkh9rnHXI5_AaZ5gHY |
| ContentType | Journal Article |
| Copyright | 2020 一般社団法人日本獣医麻酔外科学会 |
| Copyright_xml | – notice: 2020 一般社団法人日本獣医麻酔外科学会 |
| DOI | 10.2327/jjvas.51.16 |
| DatabaseTitleList | |
| DeliveryMethod | fulltext_linktorsrc |
| EISSN | 2189-6631 |
| EndPage | 22 |
| ExternalDocumentID | article_jjvas_51_2_51_16_article_char_ja |
| GroupedDBID | ALMA_UNASSIGNED_HOLDINGS ECGQY EYRJQ JSF KQ8 RJT |
| ID | FETCH-LOGICAL-j2460-26c75a291e7408b56b6b75834863ffc9c642cdf3ee820337065ad7c262554f2c3 |
| ISSN | 2189-6623 |
| IngestDate | Wed Sep 03 06:30:11 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | false |
| IsScholarly | true |
| Issue | 2 |
| Language | Japanese |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-j2460-26c75a291e7408b56b6b75834863ffc9c642cdf3ee820337065ad7c262554f2c3 |
| OpenAccessLink | https://www.jstage.jst.go.jp/article/jjvas/51/2/51_16/_article/-char/ja |
| PageCount | 7 |
| ParticipantIDs | jstage_primary_article_jjvas_51_2_51_16_article_char_ja |
| PublicationCentury | 2000 |
| PublicationDate | 20200000 |
| PublicationDateYYYYMMDD | 2020-01-01 |
| PublicationDate_xml | – year: 2020 text: 20200000 |
| PublicationDecade | 2020 |
| PublicationTitle | 日本獣医麻酔外科学雑誌 |
| PublicationTitleAlternate | 日本獣医麻酔外科学雑誌 |
| PublicationYear | 2020 |
| Publisher | 一般社団法人 日本獣医麻酔外科学会 |
| Publisher_xml | – name: 一般社団法人 日本獣医麻酔外科学会 |
| References | 42) Sugiura, S., Asano, M., Kinoshita, K., Tanimura, M. and Nabeshima, T. (2011): Risks to health professionals from hazardous drugs in Japan: A pilot study of environmental and biological monitoring of occupational exposure to cyclophosphamide. J. Oncol. Pharm. Pract. 17: 14–19. 36) 佐々木真紀子，石井範子，菊地由紀子，工藤由紀子，杉山令子，長谷部真木子 (2016): 化学療法中患者の看護にあたる看護師の抗がん剤による職業性曝露：尿中シクロフォスファミドとα-フルオロ-βアラニンの定量分析．産業衛生学雑誌58: 164–172. 15) Galbraith, E. A. and McKellar, Q. A. (1991): Pharmacokinetics and pharmacodynamics of piroxicam in dogs. Vet. Rec. 128: 561–565. 28) Matsuyama, A., Poirier, V. J., Mantovani, F., Foster, R. A. and Mutsaers, A. J. (2017): Adjuvant Doxorubicin with or without Metronomic Cyclophosphamide for Canine Splenic Hemangiosarcoma. J. Am. Anim. Hosp. Assoc. 53: 304–312. 29) Mitchell, L., Thamm, D. H. and Biller, B. J. (2012): Clinical and immunomodulatory effects of toceranib combined with low-dose cyclophosphamide in dogs with cancer. J. Vet. Intern. Med. 26: 355–362. 20) Klement, G., Baruchel, S., Rak, J., Man, S., Clark, K., Hicklin, D. J., Bohlen, P. and Kerbel, R. S. (2000): Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J. Clin. Invest. 105: R15–24. 23) Knottenbelt, C., Mellor, D., Nixon, C., Thompson, H. and Argyle, D. J. (2006): Cohort study of COX-1 and COX-2 expression in canine rectal and bladder tumors. J. Small Anim. Pract. 47: 196–200. 12) Elmslie, R. E., Glawe, P. and Dow, S. W. (2008): Metronomic therapy with cyclophosphamide and piroxicam effectively delays tumor recurrence in dogs with incompletely resected soft tissue sarcomas. J. Vet. Intern. Med. 22: 1373–1379. 40) Sorenmo K. U. Jeglum, K. A. and Helfand, S. C. (1993): Chemotherapy of canine hemangiosarcoma with doxorubicin and cyclophosphamide. J. Vet. Intern. Med. 7: 370–376. 17) Hanahan, D., Bergers, G. and Bergsland, E. (2000): Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J. Clin. Invest. 105: 1045–1047. 8) Charney, S. C., Bergman, P. J., Hohenhaus, A. E. and McKnight, J. A. (2003): Risk factors for sterile hemorrhagic cystitis in dogs with lymphoma receiving cyclophosphamide with or without concurrent administration of furosemide: 216 cases (1990–1996). J. Am. Vet. Med. Assoc. 222: 1388–1393. 11) Dore, M., Lanthier, L. and Sirois, J. (2003): Cyclooxygenase-2 expression in canine mammary tumors. Vet. Pathol. 40: 207–212. 19) Khan, K. N., Knapp, D. W., Denicola, D. B. and Harris, R. K. (2000): Expression of cyclooxygenase-2 in transitional cell carcinoma of the urinary bladder in dogs. Am. J. Vet. Res. 61: 478–481. 26) Marvel, S. J., Seguin, B., Dailey, D. D. and Thamm, D. H. (2017): Clinical outcome of partial cystectomy for transitional cell carcinoma of the canine bladder. Vet. Comp. Oncol. 15: 1417–1427. 30) Millanta, F. Asproni, P. Canale, A. Citi, S. and Poli, A. (2016): COX-2, mPGES-1, and EP2 receptor immunohistochemical expression in canine and feline malignant mammary tumors. Vet. Comp. Oncol. 14: 270–280. 33) Ogilvie, G. K., Powers, B. E., Mallinckrodt, C. H. and Withrow, S. J. (1996): Surgery and doxorubicin in dogs with hemangiosarcoma. J. Vet. Intern. Med. 10: 379–384. 7) Chan, C. M., Frimberger, A. E. and Moore, A. S. (2016): Incidence of sterile hemorrhagic cystitis in tumor-bearing dogs concurrently treated with oral metronomic cyclophosphamide chemotherapy and furosemide: 55 cases (2009–2015). J. Am. Vet. Med. Assoc. 249: 1408–1414. 41) Sorenmo, K. U., Goldschmidt, M. H., Shofer, F. S., Goldkamp, C. and Ferracone, J. (2004): Evaluation of cyclooxygenase-1 and cyclooxygenase-2 expression and the effect of cyclooxygenase inhibitors in canine prostatic carcinoma. Vet. Comp. Oncol. 2: 13–23. 24) Lana, S., U’ren, U., Plaza, S., Elmslie, R., Gustafson, D., Morley, P. and Dow, S.(2007): Continuous low-dose oral chemotherapy for adjuvant therapy of splenic hemangiosarcoma in dogs. J. Vet. Intern. Med. 21: 764–769. 14) Gardner, H. L., London, C. A., Portela, R. A., Nguyen, S., Rosenberg, M. P., Klein, M. K., Clifford, C., Thamm, D. H., Vail, D. M., Bergman, P., Crawford-Jakubiak, M., Henny, C., Locke, J. and Garrett, L. D. (2015): Maintenance therapy with toceranib following doxorubicin-based chemotherapy for canine splenic hemangiosarcoma. BMC Vet. Res. 11: 131. 25) Lavalle, G. E., Bertagnolli, A. C., Tavares, W. L., and Cassali, G. D. (2009): Cox-2 expression in canine mammary carcinomas: correlation with angiogenesis and overall survival. Vet. Pathol. 46: 1275–1280. 35) Queiroga, F. L., Pires, I., Lobo, L. and Lopes, C. S. (2010): The role of Cox-2 expression in the prognosis of dogs with malignant mammary tumors. Res. Vet. Sci. 88: 441–445. 34) Polton, G., Finotello, R., Sabattini, S., Rossi, F., Laganga, P.,Vasconi, M. E., Barbanera, A., Stiborova, K., Rohrer, Bley, C. and Marconato, L. (2018): Survival analysis of dogs with advanced primary lung carcinoma treated by metronomic cyclophosphamide, piroxicam and thalidomide. Vet. Comp. Oncol. 16: 399–408. 37) Sayasith, K., Sirois, J. and Dore, M. (2009): Molecular characterization of feline COX-2 and expression in feline mammary carcinomas. Vet. Pathol. 46: 423–429. 9) Connor, T. H., Shults, M. and Eraser, M. P. (2000): Determination of the vaporization of solution of mutagenic antineoplastic agents at 23 and 37 degrees C using a desiccator technique. Mutat. Res. 470: 85–92. 31) 桃井康行(監訳) (2006): 犬の腫瘍，pp. 116–135. インターズー，東京 38) Setyo, L., Ma, M., Bunn, T., Wyatt, K. and Wang, P. (2017): Furosemide for prevention of cyclophosphamide-associated sterile haemorrhagic cystitis in dogs receiving metronomic low-dose oral cyclophosphamide. Vet. Comp. Oncol. 15: 1468–1478. 6) Carlos, E., Fonseca, A. and Sabryna, G. C. (2016): Metronomic chemotherapy in small animal practice: An update. Asian Journal of Animal and Veterinary Advances. 11: 17–23. 10) Coussens, L. M. and Werb, Z. (2002): Inflammation and cancer. Nature 420: 860–867. 21) Knapp, D. W. Richardson. R. C. Bottoms, G. D. Teclaw, R. and Chan, T. C. (1992): Phase I trial of piroxicam in 62 dogs bearing naturally occurring tumors. Cancer Chemother. Pharmacol. 29: 214–218. 3) Best, M. P. and Fry, D. R. (2013): Incidence of sterile hemorrhagic cystitis in dogs receiving cyclophosphamide orally for three days without concurrent furosemide as part of a chemotherapeutic treatment for lymphoma: 57 cases (2007–2012). J. Am. Vet. Med. Assoc. 243: 1025–1029. 44) 山本充哉 (2019): 犬の脾臓血管肉腫におけるエトポシド，クロラムブシルおよびNSAIDsを用いたメトロノミック化学療法の治験例．動物臨床医学 28: 110–114. 43) 田村 悠，丹羽昭博，松田一哉，遠藤能史，廉澤 剛 (2017): 原発性肺腺癌の肺転移病巣に対してリン酸トセラニブによる長期治療を行った犬の1例．日獣会誌70: 52–55. 1) Alexander, C. K., Cronin, K. L., Silver, M., Gardner, H. L. and London, C. (2019): The addition metronomic chemotherapy does not improve outcome for canine splenic haemangiosarcoma. J. Small Anim. Pract. 60: 32–37. 13) Gaeta, R., Brown, D., Cohen, R. and Sorenmo, K. (2014): Risk factors for development of sterile hemorrhagic cystitis in canine lymphoma patients receiving oral cyclophosphamide: a case-control study. Vet. Comp. Oncol. 12: 277–286. 16) Hammer, A. S., Couto, C. G., Filppi, J., Getzy, D. and Shank, K. (1991): Efficacy and toxicity of VAC chemotherapy (vincristine, doxorubicin, and cyclophosphamide) in dogs with hemangiosarcoma. J. Vet. Intern. Med. 5: 160–166. 2) Asproni, P., Vignoli, M., Cancedda, S., Millanta, F., Terragni, R. and Poli, A. (2014): Immunohistiochemical expression of cyclooxygenase-2 in normal, hyperplastic and neoplastic canine lymphoid tissue. J. Comp. Pathol. 151: 35–41. 4) Browder, T., Butterfield, C. E., Kraling, B. M., Shi, B., Marshall, B., O’ Reilly, M. S. and Folkman, J. (2000): Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res. 60: 1878–1886. 5) Burton, J. H., Mitchell, L., Thamm, D. H., Dow, S. W. and Biller, B. J. (2011): Low-dose cyclophosphamide selectively decreases regulatory T cells and inhibits angiogenesis in dogs with soft tissue sarcoma. J. Vet. Intern. Med. 25: 920–926. 18) Hayes, A. M., Adams, V. J., Scase, T. J. and Murphy, S. (2007): Survival of 54 cats with oral squamous cell carcinoma in United Kingdom general practice. J. Small Anim. Pract. 48: 394–399. 32) Norris, A. M., Laing, E. J., Valli, V. E., Withrow, S. J., Macy, D. W., Ogilvie, G. K., Tomlinson, J., McCaw, D., Pidgeon, G. and Jacobs, R. M. (1992): Canine bladder and urethral tumors: a retrospective study of 115 cases (1980–1985). J. Vet. Intern. Med. 6: 145–153. 27) Matsuyama, A., Woods, J. P. and Mutsaers, A. J. (2017): Evaluation of toxicity of a chronic alternate day metronomic cyclophosphamide chemotherapy protocol in dogs with naturally occurring cancer. Can. Vet. J. 58: 51–55. 39) 島田真紀，島村俊介，松田奈穂子，茂木朋貴，片山泰章，宇塚雄次，岡村泰彦 (2013): 経口低用量術後化学療法を実施した肉腫の犬の3例．動物臨床医学22: 162–166. 22) Knapp, D. W., Richardson, R. C., Chan, T. C., Bottoms, G. D., Widmer, W. R., DeNicola, D. B., Teclaw, R., Bonney, P. L. and Kuczek, T. (1994): Piroxicam therapy in 34 dogs with transitional cell carcinoma of the urinary bladder. J. Vet. Intern. Med. 8: 273–278. |
| References_xml | – reference: 19) Khan, K. N., Knapp, D. W., Denicola, D. B. and Harris, R. K. (2000): Expression of cyclooxygenase-2 in transitional cell carcinoma of the urinary bladder in dogs. Am. J. Vet. Res. 61: 478–481. – reference: 20) Klement, G., Baruchel, S., Rak, J., Man, S., Clark, K., Hicklin, D. J., Bohlen, P. and Kerbel, R. S. (2000): Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J. Clin. Invest. 105: R15–24. – reference: 3) Best, M. P. and Fry, D. R. (2013): Incidence of sterile hemorrhagic cystitis in dogs receiving cyclophosphamide orally for three days without concurrent furosemide as part of a chemotherapeutic treatment for lymphoma: 57 cases (2007–2012). J. Am. Vet. Med. Assoc. 243: 1025–1029. – reference: 43) 田村 悠，丹羽昭博，松田一哉，遠藤能史，廉澤 剛 (2017): 原発性肺腺癌の肺転移病巣に対してリン酸トセラニブによる長期治療を行った犬の1例．日獣会誌70: 52–55. – reference: 14) Gardner, H. L., London, C. A., Portela, R. A., Nguyen, S., Rosenberg, M. P., Klein, M. K., Clifford, C., Thamm, D. H., Vail, D. M., Bergman, P., Crawford-Jakubiak, M., Henny, C., Locke, J. and Garrett, L. D. (2015): Maintenance therapy with toceranib following doxorubicin-based chemotherapy for canine splenic hemangiosarcoma. BMC Vet. Res. 11: 131. – reference: 32) Norris, A. M., Laing, E. J., Valli, V. E., Withrow, S. J., Macy, D. W., Ogilvie, G. K., Tomlinson, J., McCaw, D., Pidgeon, G. and Jacobs, R. M. (1992): Canine bladder and urethral tumors: a retrospective study of 115 cases (1980–1985). J. Vet. Intern. Med. 6: 145–153. – reference: 7) Chan, C. M., Frimberger, A. E. and Moore, A. S. (2016): Incidence of sterile hemorrhagic cystitis in tumor-bearing dogs concurrently treated with oral metronomic cyclophosphamide chemotherapy and furosemide: 55 cases (2009–2015). J. Am. Vet. Med. Assoc. 249: 1408–1414. – reference: 8) Charney, S. C., Bergman, P. J., Hohenhaus, A. E. and McKnight, J. A. (2003): Risk factors for sterile hemorrhagic cystitis in dogs with lymphoma receiving cyclophosphamide with or without concurrent administration of furosemide: 216 cases (1990–1996). J. Am. Vet. Med. Assoc. 222: 1388–1393. – reference: 24) Lana, S., U’ren, U., Plaza, S., Elmslie, R., Gustafson, D., Morley, P. and Dow, S.(2007): Continuous low-dose oral chemotherapy for adjuvant therapy of splenic hemangiosarcoma in dogs. J. Vet. Intern. Med. 21: 764–769. – reference: 31) 桃井康行(監訳) (2006): 犬の腫瘍，pp. 116–135. インターズー，東京． – reference: 38) Setyo, L., Ma, M., Bunn, T., Wyatt, K. and Wang, P. (2017): Furosemide for prevention of cyclophosphamide-associated sterile haemorrhagic cystitis in dogs receiving metronomic low-dose oral cyclophosphamide. Vet. Comp. Oncol. 15: 1468–1478. – reference: 16) Hammer, A. S., Couto, C. G., Filppi, J., Getzy, D. and Shank, K. (1991): Efficacy and toxicity of VAC chemotherapy (vincristine, doxorubicin, and cyclophosphamide) in dogs with hemangiosarcoma. J. Vet. Intern. Med. 5: 160–166. – reference: 34) Polton, G., Finotello, R., Sabattini, S., Rossi, F., Laganga, P.,Vasconi, M. E., Barbanera, A., Stiborova, K., Rohrer, Bley, C. and Marconato, L. (2018): Survival analysis of dogs with advanced primary lung carcinoma treated by metronomic cyclophosphamide, piroxicam and thalidomide. Vet. Comp. Oncol. 16: 399–408. – reference: 23) Knottenbelt, C., Mellor, D., Nixon, C., Thompson, H. and Argyle, D. J. (2006): Cohort study of COX-1 and COX-2 expression in canine rectal and bladder tumors. J. Small Anim. Pract. 47: 196–200. – reference: 1) Alexander, C. K., Cronin, K. L., Silver, M., Gardner, H. L. and London, C. (2019): The addition metronomic chemotherapy does not improve outcome for canine splenic haemangiosarcoma. J. Small Anim. Pract. 60: 32–37. – reference: 30) Millanta, F. Asproni, P. Canale, A. Citi, S. and Poli, A. (2016): COX-2, mPGES-1, and EP2 receptor immunohistochemical expression in canine and feline malignant mammary tumors. Vet. Comp. Oncol. 14: 270–280. – reference: 37) Sayasith, K., Sirois, J. and Dore, M. (2009): Molecular characterization of feline COX-2 and expression in feline mammary carcinomas. Vet. Pathol. 46: 423–429. – reference: 42) Sugiura, S., Asano, M., Kinoshita, K., Tanimura, M. and Nabeshima, T. (2011): Risks to health professionals from hazardous drugs in Japan: A pilot study of environmental and biological monitoring of occupational exposure to cyclophosphamide. J. Oncol. Pharm. Pract. 17: 14–19. – reference: 15) Galbraith, E. A. and McKellar, Q. A. (1991): Pharmacokinetics and pharmacodynamics of piroxicam in dogs. Vet. Rec. 128: 561–565. – reference: 6) Carlos, E., Fonseca, A. and Sabryna, G. C. (2016): Metronomic chemotherapy in small animal practice: An update. Asian Journal of Animal and Veterinary Advances. 11: 17–23. – reference: 13) Gaeta, R., Brown, D., Cohen, R. and Sorenmo, K. (2014): Risk factors for development of sterile hemorrhagic cystitis in canine lymphoma patients receiving oral cyclophosphamide: a case-control study. Vet. Comp. Oncol. 12: 277–286. – reference: 2) Asproni, P., Vignoli, M., Cancedda, S., Millanta, F., Terragni, R. and Poli, A. (2014): Immunohistiochemical expression of cyclooxygenase-2 in normal, hyperplastic and neoplastic canine lymphoid tissue. J. Comp. Pathol. 151: 35–41. – reference: 21) Knapp, D. W. Richardson. R. C. Bottoms, G. D. Teclaw, R. and Chan, T. C. (1992): Phase I trial of piroxicam in 62 dogs bearing naturally occurring tumors. Cancer Chemother. Pharmacol. 29: 214–218. – reference: 28) Matsuyama, A., Poirier, V. J., Mantovani, F., Foster, R. A. and Mutsaers, A. J. (2017): Adjuvant Doxorubicin with or without Metronomic Cyclophosphamide for Canine Splenic Hemangiosarcoma. J. Am. Anim. Hosp. Assoc. 53: 304–312. – reference: 29) Mitchell, L., Thamm, D. H. and Biller, B. J. (2012): Clinical and immunomodulatory effects of toceranib combined with low-dose cyclophosphamide in dogs with cancer. J. Vet. Intern. Med. 26: 355–362. – reference: 18) Hayes, A. M., Adams, V. J., Scase, T. J. and Murphy, S. (2007): Survival of 54 cats with oral squamous cell carcinoma in United Kingdom general practice. J. Small Anim. Pract. 48: 394–399. – reference: 33) Ogilvie, G. K., Powers, B. E., Mallinckrodt, C. H. and Withrow, S. J. (1996): Surgery and doxorubicin in dogs with hemangiosarcoma. J. Vet. Intern. Med. 10: 379–384. – reference: 10) Coussens, L. M. and Werb, Z. (2002): Inflammation and cancer. Nature 420: 860–867. – reference: 17) Hanahan, D., Bergers, G. and Bergsland, E. (2000): Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J. Clin. Invest. 105: 1045–1047. – reference: 41) Sorenmo, K. U., Goldschmidt, M. H., Shofer, F. S., Goldkamp, C. and Ferracone, J. (2004): Evaluation of cyclooxygenase-1 and cyclooxygenase-2 expression and the effect of cyclooxygenase inhibitors in canine prostatic carcinoma. Vet. Comp. Oncol. 2: 13–23. – reference: 35) Queiroga, F. L., Pires, I., Lobo, L. and Lopes, C. S. (2010): The role of Cox-2 expression in the prognosis of dogs with malignant mammary tumors. Res. Vet. Sci. 88: 441–445. – reference: 5) Burton, J. H., Mitchell, L., Thamm, D. H., Dow, S. W. and Biller, B. J. (2011): Low-dose cyclophosphamide selectively decreases regulatory T cells and inhibits angiogenesis in dogs with soft tissue sarcoma. J. Vet. Intern. Med. 25: 920–926. – reference: 11) Dore, M., Lanthier, L. and Sirois, J. (2003): Cyclooxygenase-2 expression in canine mammary tumors. Vet. Pathol. 40: 207–212. – reference: 12) Elmslie, R. E., Glawe, P. and Dow, S. W. (2008): Metronomic therapy with cyclophosphamide and piroxicam effectively delays tumor recurrence in dogs with incompletely resected soft tissue sarcomas. J. Vet. Intern. Med. 22: 1373–1379. – reference: 39) 島田真紀，島村俊介，松田奈穂子，茂木朋貴，片山泰章，宇塚雄次，岡村泰彦 (2013): 経口低用量術後化学療法を実施した肉腫の犬の3例．動物臨床医学22: 162–166. – reference: 40) Sorenmo K. U. Jeglum, K. A. and Helfand, S. C. (1993): Chemotherapy of canine hemangiosarcoma with doxorubicin and cyclophosphamide. J. Vet. Intern. Med. 7: 370–376. – reference: 4) Browder, T., Butterfield, C. E., Kraling, B. M., Shi, B., Marshall, B., O’ Reilly, M. S. and Folkman, J. (2000): Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res. 60: 1878–1886. – reference: 44) 山本充哉 (2019): 犬の脾臓血管肉腫におけるエトポシド，クロラムブシルおよびNSAIDsを用いたメトロノミック化学療法の治験例．動物臨床医学 28: 110–114. – reference: 36) 佐々木真紀子，石井範子，菊地由紀子，工藤由紀子，杉山令子，長谷部真木子 (2016): 化学療法中患者の看護にあたる看護師の抗がん剤による職業性曝露：尿中シクロフォスファミドとα-フルオロ-βアラニンの定量分析．産業衛生学雑誌58: 164–172. – reference: 26) Marvel, S. J., Seguin, B., Dailey, D. D. and Thamm, D. H. (2017): Clinical outcome of partial cystectomy for transitional cell carcinoma of the canine bladder. Vet. Comp. Oncol. 15: 1417–1427. – reference: 9) Connor, T. H., Shults, M. and Eraser, M. P. (2000): Determination of the vaporization of solution of mutagenic antineoplastic agents at 23 and 37 degrees C using a desiccator technique. Mutat. Res. 470: 85–92. – reference: 22) Knapp, D. W., Richardson, R. C., Chan, T. C., Bottoms, G. D., Widmer, W. R., DeNicola, D. B., Teclaw, R., Bonney, P. L. and Kuczek, T. (1994): Piroxicam therapy in 34 dogs with transitional cell carcinoma of the urinary bladder. J. Vet. Intern. Med. 8: 273–278. – reference: 27) Matsuyama, A., Woods, J. P. and Mutsaers, A. J. (2017): Evaluation of toxicity of a chronic alternate day metronomic cyclophosphamide chemotherapy protocol in dogs with naturally occurring cancer. Can. Vet. J. 58: 51–55. – reference: 25) Lavalle, G. E., Bertagnolli, A. C., Tavares, W. L., and Cassali, G. D. (2009): Cox-2 expression in canine mammary carcinomas: correlation with angiogenesis and overall survival. Vet. Pathol. 46: 1275–1280. |
| SSID | ssib031740830 ssj0003304624 ssib022766668 |
| Score | 2.182279 |
| Snippet | 28頭の犬の悪性腫瘍症例に術後補助的化学療法として、CPMを10～35 mg/m2およびピロキシカム0.3... |
| SourceID | jstage |
| SourceType | Publisher |
| StartPage | 16 |
| SubjectTerms | 低用量メトロノーム療法 出血性膀胱炎 |
| Title | メトロノーム療法による術後補助的化学療法を行った犬の悪性腫瘍28例 |
| URI | https://www.jstage.jst.go.jp/article/jjvas/51/2/51_16/_article/-char/ja |
| Volume | 51 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| ispartofPNX | 日本獣医麻酔外科学雑誌, 2020, Vol.51(2), pp.16-22 |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtR1Na9RANJR68SKKit_04Jxk180kmcwcJ7tZiqIgtNBb2KQJuIcqtfXgyd1VKG31oCgqgpaCorVevEr_TNzu_gzfe5nsLkWhFoQQ3r557837SHjzZmcmlnXVSxMFeS-t1HzfgQLFzyoxVFqVdJHzxMP_2uhjMLdui9l598aCtzA1vTyxaml1Ja4mj_64r-QoUQUcxBV3yf5DZEdCAQEwxBfuEGG4HyrGLHSYdJi2DSBliWmUmNAAQb1sqrHQZ0oxyVkoWOAw5VGTzXRAAC_lAAAYifKVw0KPBSGTdcIAVx0xUjOtSKBm0iVMnSmBAOigxV_64kxxI1nWy94dA6gmcqHkUVOI7MClNQE1pn1klx7pDF0A3OCgtUs6BpNDbuRQPtMeAXWSCuIb1CHpG4AMxQJtAJCqyBTtkik-9qbsCZsUUwFhJGokRxPNJK-JqqOzgKmBTzD-QAUcEhVABMb0hUaSGAX2bOglXmMyhdy6SSrY6GsiI7-iPuBat7Sa6H10NEYa1LDxInpDRl5SJb2Z8eG10dtJ7RK9jC6WxmGaXIumBGTKKJwueU5f-w9-dvGxVXqcrGCkqCpCFHvHq-kkzmR5k23N8cJ3JyY9itRpi4lBWLFX_WB6h9E_LjBotx-2HlQ9u2ofOESdhmXmbYyIKvLsiOPNFlHZgNsZozbUVMe479u4DPjmnVEO4tyHgn5cgsPw2oUqpTaat8X5P0Hfyh6ZXGz7ReWuT6gGQ9o2FHjl4lAar86dtE6YQnNGF-qcsqbardNWlPe28t5a3tvNe8_z3s-893Hwtrv_41Xe2cm7a3l3Y7j1sr-3Odx-31__Mnj3pL_5ur_7ydB0Xwy3NvPOdt75MFj_lne-73e_7j_-PHy6M3jzjMtfextnrPlmOFefrZhPrFTa3BW1CheJ77W4slM0M_ZELGLfk44rhZNliUqEy5PFzElTqBQcB9dEtBb9hAsOZUjGE-esNb10byk9Z814GR6WKGXSigUuxogVZIFappIsy2LP5ectv_BHdL84Ryc6bKQuHJnzonUcX6BiyvSSNb2yvJpehiJiJb5CUf8NxDPjcA |
| linkProvider | Colorado Alliance of Research Libraries |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=%E3%83%A1%E3%83%88%E3%83%AD%E3%83%8E%E3%83%BC%E3%83%A0%E7%99%82%E6%B3%95%E3%81%AB%E3%82%88%E3%82%8B%E8%A1%93%E5%BE%8C%E8%A3%9C%E5%8A%A9%E7%9A%84%E5%8C%96%E5%AD%A6%E7%99%82%E6%B3%95%E3%82%92%E8%A1%8C%E3%81%A3%E3%81%9F%E7%8A%AC%E3%81%AE%E6%82%AA%E6%80%A7%E8%85%AB%E7%98%8D28%E4%BE%8B&rft.jtitle=%E6%97%A5%E6%9C%AC%E7%8D%A3%E5%8C%BB%E9%BA%BB%E9%85%94%E5%A4%96%E7%A7%91%E5%AD%A6%E9%9B%91%E8%AA%8C&rft.au=%E5%8F%8A%E5%B7%9D%2C+%E5%97%A3%E7%AB%A0&rft.au=%E6%9C%A8%E5%86%85%2C+%E5%85%85&rft.au=%E9%A3%AF%E5%A1%9A%2C+%E9%82%A6%E6%B4%8B&rft.au=%E7%95%A0%E5%B1%B1%2C+%E6%B4%8B%E4%B9%8B&rft.date=2020&rft.pub=%E4%B8%80%E8%88%AC%E7%A4%BE%E5%9B%A3%E6%B3%95%E4%BA%BA+%E6%97%A5%E6%9C%AC%E7%8D%A3%E5%8C%BB%E9%BA%BB%E9%85%94%E5%A4%96%E7%A7%91%E5%AD%A6%E4%BC%9A&rft.issn=2189-6623&rft.eissn=2189-6631&rft.volume=51&rft.issue=2&rft.spage=16&rft.epage=22&rft_id=info:doi/10.2327%2Fjjvas.51.16&rft.externalDocID=article_jjvas_51_2_51_16_article_char_ja |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2189-6623&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2189-6623&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2189-6623&client=summon |